162 related articles for article (PubMed ID: 35831518)
1. The effect of smoking on survival in lung carcinoma patients with brain metastasis: a systematic review and meta-analysis.
Chawla S; Tewarie IA; Zhang QO; Hulsbergen AFC; Mekary RA; Broekman MLD
Neurosurg Rev; 2022 Oct; 45(5):3055-3066. PubMed ID: 35831518
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
[TBL] [Abstract][Full Text] [Related]
3. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
4. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
5. The impact of smoking on survival in renal cell carcinoma: a systematic review and meta-analysis.
Xu Y; Qi Y; Zhang J; Lu Y; Song J; Dong B; Kong W; Xue W; Huang Y
Tumour Biol; 2014 Jul; 35(7):6633-40. PubMed ID: 24699995
[TBL] [Abstract][Full Text] [Related]
6. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Dai L; Jin B; Liu T; Chen J; Li G; Dang J
EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
[TBL] [Abstract][Full Text] [Related]
7. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U; Soo RA; Peters S; Tsourti Z; Zygoura P; Vervita K; Han JY; De Castro J; Coate L; Früh M; Hashemi SMS; Nadal E; Carcereny E; Sala MA; Bernabé R; Provencio M; Cuffe S; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA
ESMO Open; 2022 Jun; 7(3):100507. PubMed ID: 35696746
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
10. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Raphael J; Batra A; Boldt G; Shah PS; Blanchette P; Rodrigues G; Vincent MD
Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
[TBL] [Abstract][Full Text] [Related]
12. Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Lin K; Lin J; Huang Z; Fu J; Yi Q; Cai J; Khan M; Yuan Y; Bu J
Front Pharmacol; 2022; 13():881493. PubMed ID: 35645829
[No Abstract] [Full Text] [Related]
13. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Lee CK; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst RS; Gralla RJ; Mok T; Yang JC
JAMA Oncol; 2018 Feb; 4(2):210-216. PubMed ID: 29270615
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of the amount of tobacco smoking in non-small cell lung cancer--differences between adenocarcinoma and squamous cell carcinoma.
Okamoto T; Suzuki Y; Fujishita T; Kitahara H; Shimamatsu S; Kohno M; Morodomi Y; Kawano D; Maehara Y
Lung Cancer; 2014 Aug; 85(2):125-30. PubMed ID: 24976334
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological and survival differences between never and ever smokers with non-small cell lung cancer.
Muallaoglu S; Karadeniz C; Mertsoylu H; Ayberk Besen A; Sezer A; Murat Sedef A; Kose F; Ozyilkan O
J BUON; 2014; 19(2):453-8. PubMed ID: 24965406
[TBL] [Abstract][Full Text] [Related]
17. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
Liu W; Huo G; Chen P
Front Immunol; 2022; 13():909027. PubMed ID: 35799785
[TBL] [Abstract][Full Text] [Related]
19. Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC.
Qin BD; Jiao XD; Wang Y; Wu Y; Ling Y; Liu K; Zang YS
Lung Cancer; 2022 Aug; 170():91-97. PubMed ID: 35728482
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis.
Brar K; Taslimi S; Ellenbogen Y; Deng J; Hou W; Moraes FY; Glantz M; Zacharia BE; Tan A; Ahluwalia MS; Khasraw M; Zadeh G; Mansouri A
World Neurosurg; 2022 Feb; 158():e87-e102. PubMed ID: 34688937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
